Posts

Colon Cancer Alliance Announces Corporate Name Change

National Non-Profit Begins A New Chapter Revealing New Name, New Logo, & Inclusive Mission

November 2, 2017 (Washington, D.C.) –  Effective immediately, the Colon Cancer Alliance is now the Colorectal Cancer Alliance, embracing the entire colorectal cancer community, adopting a new name, and committing to a powerful mission: To empower a nation of allies who work with us to provide support for patients and families, caregivers, and survivors; to raise awareness of preventative measures; and inspire efforts to fund critical research. The official rebrand brings an inclusive identity that ensures accuracy, leadership, and most important- alliance within the colorectal cancer community.

The Launch of a Nation of Allies – The name change is part of a larger rebranding effort for the organization which includes a new logo and visual identity, new website, and commitment to accuracy for the entire colorectal cancer community.

With the strategic mission of servicing both colon and rectal cancer patients, combined with fierce determination to end colorectal cancer within our lifetime, the Colorectal Cancer Alliance set three ambitious goals:  

  • Double the number of patients served by 2021
  • Save 100,000 lives with preventive screening in the next 10 years
  • Invest $10 million in critical research

The organization launched nationofallies.org a national network for advocates and allies to show their support in eliminating colorectal cancer within our lifetime and highlight ways individuals can educate their local communities on prevention and screening options. The focus of the “Nation of Allies” theme is to empower individuals to work with the Colorectal Cancer Alliance to provide support to patients and families, survivors, and caregivers, to raise awareness of preventative measures, and to inspire efforts to fund critical research.

“On behalf of the entire Colorectal Cancer Alliance community, we are beyond thrilled to be launching this new name, logo and visual identity to help continue to grow as the leading resource for patients and families,” said Michael Sapienza, CEO of the Colorectal Cancer Alliance.  The Colorectal Cancer Alliance is the oldest, largest colorectal cancer non-profit in the nation and I am proud to part of this amazing evolution” Michael Sapienza, CEO, Colorectal Cancer Alliance.

Nearly a third of all colorectal cancers diagnosed this year will be rectal cancer. Nearly 40,000 new U.S. cases of rectal cancer will be diagnosed in 2017 alone. Colon cancer and rectal cancer are often grouped together because they have a lot in common—including symptoms—but they are different, depending on where they originate. Through this rebrand, the Colorectal Cancer Alliance has extended its reach into the colorectal cancer community by 30% while committing to align a nation of allies, together in the mission to end this disease.

“We share a common goal of eradicating colorectal cancer through prevention and early detection,” said Kevin Conroy, chairman and CEO of Exact Sciences and long time national partner of the Colorectal Cancer Alliance. “As this new chapter begins for the Colorectal Cancer Alliance, we are committed to working together to increase awareness about the importance of getting screened for this preventable disease.”

The name change and brand reveal debuted alongside the 2017 Tomorrow Can’t Wait National Conference at the Cleveland Clinic on November 1st. Conference attendees consisting of patients, survivors, and caregivers, had front row seats and true VIP access at the Rock & Roll Hall of Fame for the official kick-off. The nonprofit decided on the Rock & Roll Hall of Fame from so many requests from cancer patients attending the conference. You can visit the Facebook live rebrand announcement at tomorrowcantwait.org.

“To be surrounded by patients and families at such a historic event, celebrating new beginnings and amazing accomplishments is truly one of the most important nights of my life. We are grateful to this nation of allies supporting our vision: A world free of colorectal cancer within our lifetime” Michael Sapienza, CEO.

The Colorectal Cancer Alliance worked with Alexandria, VA based creative agency Grafik on the new identity and overall rebranding efforts.

To learn more about the rebrand and Colorectal Cancer Alliance, visit nationofallies.org.

 

About the Colorectal Cancer Alliance

The Colorectal Cancer Alliance is a national nonprofit committed to ending colorectal cancer. Working with our nation of passionate allies, we diligently support the needs of patients and families, caregivers, and survivors, eagerly raise awareness of preventative screening, and continually strive to fund critical research. As allies in the struggle, we are fiercely determined to end colorectal cancer within our lifetime. For more information, visit nationofallies.org.

Over 200 Colorectal Cancer Patients, Survivors, and Caregivers to Take Part in the 15th Annual National Conference focused on Patient Empowerment

Now in its 15th year, the Colon Cancer Alliance’s annual National Conference will honor and celebrate colorectal patients and families, survivors, and caregivers. This two-day conference at the Cleveland Clinic in Cleveland, Ohio, is made up of those who have been personally affected by colorectal cancer in their lives. The theme of the conference is “Tomorrow can’t wait,” and this year’s focus is all about patient empowerment.

“An empowered patient is educated in all aspects of the patient journey, understands the need for an open and honest dialogue with their healthcare team, and is able to advocate for themselves and others. The Colon Cancer Alliance understands that now is the time to empower our community: Tomorrow can’t wait” – Michael Sapienza, CEO, Colon Cancer Alliance.

Close to 75 percent of conference attendees are colorectal cancer patients, and 35 percent of them are currently undergoing treatments. Attendees will participate and discover through interactive discussion the important role that patient empowerment plays in all aspects of a colorectal cancer diagnosis.

“Feeling like you have a community of support and information to help you along your journey is the most important goal of this event. We want attendees to feel empowered, educated, and to provide a shared sense of camaraderie,” Michael Sapienza said.

The conference will empower all participants. The theme of Tomorrow Can’t Wait carries into the agenda packed with empowerment-focused topics ranging from effective communication when talking to healthcare professionals, to support around important needs and challenges caregivers face. Additionally, attendees will participate in out-of-the-box plenary sessions that include the following:

  • Clinical Trials:  What All Patients Need To Know
  • Case Study Interactive Discussion with Leading Healthcare Professionals
  • Relationships and Intimacy

This year’s conference is sold out, but the Colon Cancer Alliance will livestream the event. The event link can be found here and will be live Nov. 1. This event was made possible through the support of our trusted partners: Genentech, Lilly Oncology, Array BioPharma, Bristol-Myers Squibb, BTG, Merck, Taiho Oncology, Clinical Genomics, Amgen, Boehringer Ingelheim, Boston Biomedical, Epigenomics and Igynta, and the Cleveland Clinic.

A very special announcement will be made the first night of the conference…stay tuned for more exciting details.

About Colon Cancer Alliance
The Colon Cancer Alliance is a national nonprofit committed to ending colon cancer within our lifetime. Our mission is to knock colon cancer out of the top three cancer killers. We are doing this by championing prevention, funding cutting-edge research and providing the highest quality patient support services. www.ccalliance.org

For more information on the conference, please visit our conference page.

Statement from Michael Sapienza, CEO of the Colon Cancer Alliance, on FDA Approval of VARUBI Intravenous Administration

October 26, 2017 (WASHINGTON) – VARUBI, a highly anticipated treatment for colorectal patients who suffer from delayed chemotherapy-induced nausea, has been approved by the Food and Drug Administration for delivery via one-time intravenous administration. This new way to administer VARUBI provides healthcare providers with flexibility to treat patients in a more individualized manner.

VARUBI addresses delayed nausea that can arrive 24 to 120 hours after the start of chemotherapy. If nausea is not managed aggressively, it can lead to weight loss, dehydration, and hospitalization. Quality-of-life issues are incredibly important for patients and families dealing with colorectal cancer and chemotherapy. The approval of VARUBI is good step forward in addresses some of these concerns.

For more information about VARUBI, please access: https://globenewswire.com/news-release/2017/10/25/1153687/0/en/TESARO-Announces-U-S-FDA-Approval-of-VARUBI-IV-for-Delayed-Nausea-and-Vomiting-Associated-With-Cancer-Chemotherapy.html

In This Together To Raise $1.5 million Colon Cancer Alliance’s Annual Gala Exceeds Fundraising Goal For Critical Patient Programs

National non-profit the Colon Cancer Alliance hosted its Annual Blue Hope Bash on Thursday, October 19th at the Andrew Mellon Auditorium in Washington, D.C.

The Blue Hope Bash, in its 7th year, is the premiere fundraising gala of the Colon Cancer Alliance that brings together both individuals and corporations that are passionate about supporting our mission to end colon cancer within our lifetime. Since the event’s inception in 2010, the event has raised more than $5 million. This year’s sold out event brought together over 600 attendees and raised a record-breaking $1.5 million support their mission and strategic plan: to invest $10 million in research, save 100,000 lives through increased screening and double the number of patients and families the Colon Cancer Alliance serves.

The theme this year was “In This Together” in which NBC’s Weekend “Today Show” Co-Anchor Craig Melvin carried the theme in emceeing the event and sharing his own connection with the disease when his brother Lawrence, was diagnosed with Stage 4 colon cancer at age 39. Craig’s brother Lawrence was in attendance at the Bash.

“Seeing and hearing the stories of so many who’ve beaten this dreadful disease was awe-inspiring for me and my brother,” said Craig Melvin. “Raising money and awareness was the goal, but it sure was a lot of fun too. I was honored to be a part of an evening filled with so much hope and love.”

“We are beyond thrilled at the impact of the Blue Hope Bash only in it’s 7th year,” said CEO of the Colon Cancer Alliance Michael Sapienza. “This will offer Colon Cancer Alliance the opportunity to head into 2018 focused on research, patients, and their families, and preventing this disease before it starts.”

The evening also announced the launch of the Michelle Benaim Memorial Fund. Michelle and her husband Avi were the Co-Chairs of the Blue Hope Bash. Michelle Benaim was diagnosed with stage IV colon cancer in 2015 at age 47. Michelle unfortunately passed away on September 30th at the age of 49. The Michelle Benaim Memorial Fund will be used to increase screening for the under-50 population and provide assistance to underserved populations who are impacted by colorectal cancer.

Other evening highlights included awarding the Erica & Michael Paul Memorial Award to Lyn Ferriero for her infectious drive, selfless dedication and generous service to the Colon Cancer Alliance, as well a drawing one lucky winner to win a custom 2018 Porsche Boxster. The winner of the custom 2018 Porsche Boxster was Stu and Susan Lisabeth from New York.

The Colon Cancer Alliance would like to thank their top tier sponsors Mike & Amy Aquilino and Jay & Lyn Ferriero for their generous support of the Blue Hope Bash.

For post event photos visit www.bluehopebash.org.

Two Clevelanders Diagnosed with Colorectal Cancer in their Mid-Twenties Prepare for the 2017 Cleveland Undy Run/Walk

Cleveland, OH (Sept. 8, 2017) – Cleveland residents Darcy Egan and Eric Lucas have two things in common: they were both in their mid-twenties when they were diagnosed with colorectal cancer and they are both determined to spread the word about what was once considered an “old man’s disease.” They have each formed teams that will be participating in Colon Cancer Alliance’s 2017 Cleveland Undy Run/Walk on Sept. 30 at The Flats at East Bank.

“I had been having colorectal problems when I was in college, so I went to see a doctor. The doctor thought I was too young for it to be serious, but it didn’t go away,” said Lucas. “When I found out about the diagnosis, I was confused about why no one would have taken the initiative to investigate and be proactive.”

According to a study in the Journal of the American Medical Association, colorectal cancers are on the rise in adults under the age of 55. However, the recommended age to begin screening for colorectal cancer is 50, unless you have a family history. With no family history of colorectal cancer, the potential for diagnosis flew under the radar for both Lucas and Egan.

Egan, who is physically active, went to the doctor for a routine check-up. During that check-up, her primary care physician recommended that she see a gastroenterologist who would later perform her colonoscopy.

“This was my first time hearing about familial adenomatous polyposis (FAP), the disease that led to my colorectal cancer diagnosis. I had no symptoms. I was a little pale, so initially the doctors thought that I might’ve been anemic,” said Egan.

Although the two have yet to meet, they’re both patients at Cleveland Clinic, which is a leader in colorectal cancer treatment and research. Cleveland Clinic is a long-time sponsor of the Undy Run/Walk, an event that draws hundreds of participants each year, the majority of whom have a connection to colorectal cancer.

Every year, participants hit the trails in fun outfits in a show of solidarity and support for colorectal cancer patients, survivors and their families. Funds raised from the Cleveland Undy Run/Walk go toward supporting the mission of the Colon Cancer Alliance whose goal is to knock colon cancer out of the top three cancer killers by championing prevention, funding cutting-edge research and providing the highest quality patient support services.

“Colorectal cancer is both preventable and curable with the appropriate screening and interventions. We are dedicated to raising awareness and starting conversations about this disease with the ultimate goal of saving lives. The last two years of this race in Cleveland have been amazing. It is incredible to see so many people participate and support the cause in what is a very fun event. It is also important to note that a portion of the funds raised stay right here in Cleveland for the benefit of our community,” said Matthew Kalady, M.D., director of The Sanford R. Weiss, MD, Center for Hereditary Colorectal Neoplasia and co-director of the Colorectal Cancer Program at Cleveland Clinic.

For his first Undy Run, Lucas formed a team called “the Crimson Butts,” a fun ode to the time he spent undergoing radiation treatment. Egan and her team, “Darcy and the Polyps,” will be participating for the second year in a row with the goal of beating her record from last year. At the 2016 Cleveland Undy Run/Walk, she raised $9,000 with a team of 120 people.

“We try to make it as lighthearted as possible. I hope the fun element makes it easier for people to talk about it,” says Egan. “Whether you think you’re in perfect health or not, make sure you pursue these symptoms.”

In the state of Ohio, 5,450 residents are expected to be diagnosed with colorectal cancer and 2,140 residents are expected to pass away as a result of colorectal cancer. However, colorectal cancer is highly treatable, if detected early.

To join Eric Lucas and Darcy Egan at the 2017 Cleveland Undy Run/Walk, please visit the Cleveland Undy Run/Walk page to register and form your own team.

###

About the Colon Cancer Alliance

The Colon Cancer Alliance is a national nonprofit committed to ending colon cancer within our lifetime. Working with our nation of passionate advocates, we are empowered to support the needs of patients and survivors, eager to raise awareness of preventative screening, and poised to help fund critical research. We are fiercely determined to end colon cancer once and for all. www.ccalliance.org

 

Colon Cancer Alliance Announces New Appointments to Board of Directors

The Colon Cancer Alliance is thrilled to announce the addition of two new members to the Board of Directors, David Schoeman, Senior Partner in the New York Office of McKinsey & Company, and Lee Dranikoff, Managing Director at American Studies. Both members have a personal understanding of colorectal cancer and its impact, which deepens their commitment to helping others affected and to one day finding a cure.

“It is with great enthusiasm that we welcome our newest board members. Both David and Lee embody the essence of leadership and bring strong direction and positive energy to the table,” Michael Sapienza, CEO.

Lee Dranikoff, JD – Lee joined American Securities in 2003. He manages the overall deployment of the functional experts within the Resources Group and directly leads the in-house Strategy Team in the U.S. In this capacity, Lee directs the Resources Group support of due diligence on prospective investments, as well as the extensive Shared Vision process that is used at all portfolio companies. Prior to McKinsey, Lee worked as an attorney at Weil, Gotshal & Manges. Lee received a BA and an MA in Economics from Johns Hopkins University and a JD from Harvard Law School.

David Schoeman, MBA – David is a Senior Partner in the New York Office of McKinsey & Company where he servers Private Equity firms and their portfolio companies, Banks and Insurance carriers. Prior to joining McKinsey, David was a systems developer at Morgan Stanley supporting the Prime Brokerage, Clearing, and Custody businesses David received an MBA from Columbia Business School and BA in Economics and History from Northwestern University. He is a published writer on bank economics and school finance reform.

“The Colon Cancer Alliance is working tirelessly to extend its reach into the colorectal cancer community. By engaging new board leaders to uphold and encompass our mission, we are on the best path forward with the addition of Lee Dranikoff and David Shoeman,” Michael Sapienza, CEO.

About the Colon Cancer Alliance

The Colon Cancer Alliance is a national nonprofit committed to ending colon cancer within our lifetime. Working with our nation of passionate advocates, we are empowered to support the needs of patients and survivors, eager to raise awareness of preventative screening, and poised to help fund critical research. To learn more visit https://www.ccalliance.org/

Colon Cancer Alliance Announces New Chairman and Vice Chairman of the Board

Colon Cancer Alliance announced today the appointment of John Backus as the new Chairman of its Board and of Carmen Marc Valvo as Vice Chairman.

“It is with great enthusiasm that we welcome and congratulate the newly appointed Chairman, John Backus, our Vice Chair, Carmen Marc Valvo and our brand new members, David Schoeman and Lee Dranikoff. The accomplishments of these remarkable leaders cannot be overstated and, on behalf of the entire Colon Cancer Alliance, I am thrilled to welcome them in their new roles.”

-Michael Sapienza
CEO

John Backus
Chairman of the Board of Directors

Based in the national capital region, John is a seasoned technology investor and entrepreneur with over two decades of experience investing in and managing rapidly growing companies. Before becoming a venture capitalist, he co-founded US Order, which revolutionized online banking, went public in 1995 and was sold to Visa. . John holds a B.A. in Economics from Stanford University and an M.B.A. from Stanford University Graduate School of Business.

“John Backus has a prominent background as a value creator and we are thrilled to have his leadership and governance,” Michael Sapienza, CEO. “We are truly well positioned to enter the next phase of our development and it is with gratitude and admiration that I welcome him as the new Chairman.”

Carmen Marc Valvo
Vice Chairman of the Board of Directors

Carmen Marc Valvo, an American fashion designer, has used his designs as a platform to raise awareness about colon cancer all over the US. Carmen is an Entertainment Industry Foundation (EIF) Ambassador and has appeared in a PSA with Vanessa Williams for the National Colorectal Cancer Research Alliance (NCCRA).  As a colon cancer survivor, Carmen Marc Valvo has been working with Katie Couric since 2004 when she partnered with the organizers of New York Fashion Week. Carmen has been honored by numerous organizations including Gilda’s Club World Wide, the National Coalition for Cancer Survivorship, the American Cancer Society, and the Colon Cancer Alliance.

“Carmen Marc Valvo has a contagious energy that is both inspiring and influential to the colorectal cancer community,” Michael Sapienza, CEO. “His ability to connect, resonate, and lead patients, survivors & families, and the entire Colon Cancer Alliance organization is unsurpassable.”

The Colon Cancer Alliance would also like to thank Joe Frick for his time as the past board Chairman. “Joe has been a tremendous board chair, guiding CCA through many challenges and new opportunities. I’m personally grateful for his guidance and continued support,” Michael Sapienza, CEO.

About the Colon Cancer Alliance

The Colon Cancer Alliance is a national nonprofit committed to ending colon cancer within our lifetime. Working with our nation of passionate advocates, we are empowered to support the needs of patients and survivors, eager to raise awareness of preventative screening, and poised to help fund critical research. We are fiercely determined to end colon cancer once and for all. www.ccalliance.org

Unexpected Diagnosis Leads to Lifetime Partnership with the Leading Colorectal Cancer Organization

Long Branch, NJ (June 21) – “I didn’t expect to have cancer. I didn’t have any symptoms,” says Michele Battista, Jersey Shore Undy Run/Walk volunteer and fierce colon cancer advocate. This year marks Battista’s five-year “Cancer-versary,” as she calls the day when she was diagnosed with cancer. Checking off her list of things to do once she turned 50, she made an appointment with Red Bank Gastroenterology for a routine colonoscopy. It was during that appointment, she was diagnosed with stage 3c colon cancer at the age of 50.

“It’s bittersweet. Today seems so far away from when I first heard the words ‘you have cancer’, five years ago,” says Battista as she reflects on her Cancer-versary. She is now cancer-free and continually advocating for colon cancer patients and survivors through her work with Colon Cancer Alliance, an organization dedicated to knocking colon cancer out of the top three cancer killers by championing prevention, funding cutting-edge research and providing the highest quality patient support services.

She found out about Colon Cancer Alliance’s annual Jersey Shore Undy Run/Walk from a flyer hanging up in the Red Bank Gastroenterology’s office while supporting a family member during their colonoscopy. The Jersey Shore Undy Run/Walk takes a light-hearted approach to a serious and often times frightening subject. Participants sport silly, underwear-themed costumes in show of support for colon cancer patients, caregivers and families. This year’s event will take place on Saturday, July 15th at the Great Lawn at Pier Village in Long Branch, New Jersey.

Too ill to walk or volunteer in the Undy after initially hearing about it, she signed up the following year. She has returned every year for the last five years, managing to walk in the event, in spite of neuropathy in her feet as a result of chemotherapy which makes it difficult to run, walk or stand for long periods of time. In 2016, she took 3rd place in the Female Survivor category at 56 minutes.

“We are empowered by the strength and resilience of our community of survivors and caregivers. They are the heartbeat of this organization. With their assistance and dedication, the Undy Run/Walk series has become an amazing source of support and we are able to leave a footprint in each community we serve,” says Michael Sapienza, Colon Cancer Alliance CEO. Any day of the week, Battista can be found rocking various shades of blue encouraging everyone around her to get their colonoscopies. “The colonoscopy is the easy part, the surgery and chemo are the hard part,” says Battista.

In 2017, approximately 95,520 Americans will be diagnosed with colon cancer, and approximately 50,260 will die from the disease. In New Jersey alone, there have been 4,280 diagnoses & 1,510 deaths this year. If detected early enough, colon cancer is highly treatable. Although, she’s stopped counting a long time ago, Battista has inspired dozens of people to get their colonoscopies. A woman on a mission, Battista cannot be stopped. Her team, #RBGastro, will be at the Jersey Shore Undy again this year, after winning the award for largest team two years in a row.

Monies raised from the event support Colon Cancer Alliance’s local partner, Monmouth Medical Center. The award will be used to add colon cancer education to their programs to educate women over 50 and their spouses. Funds will also be used for lab and patient exam fees.

The event is sponsored by Ethicon Endo-Surgery, Inc. For more information, please visit www.undyrunwalk.org.
Registration fees:
5K Adult (14 and older) – $35 Advance/$40 Race Day
5K Youth (6-13) – $30 Advance/$35 Race Day
1 Mile Fun Run (all ages, Children 5 and younger are free) – $30 Advance/$35 Race Day

The Undy Run/Walk is July 15 in Great Lawn at Pier Village in Long Branch. Onsite registration begins at 7:00 a.m., and the run/walk begins at 8:00 a.m. For more information or to register, visit www.undyrunwalk.org, and click on Jersey Shore, NJ.

###

The Colon Cancer Alliance’s mission is to knock colon cancer out of the top three cancer killers. This is accomplished by championing prevention, funding cutting-edge research, and providing the highest quality patient support services. For more information, visit www.ccalliance.org.

Colon Cancer Alliance Awarded Platinum Status by GuideStar

June 9TH, Washington, DC- The Colon Cancer Alliance (CCA) has received Platinum status on GuideStar, the premier ranking website for non-profits. Of the more than 340,000 nonprofits in GuideStar’s database who provided industry data to compete for this achievement, less than 1% received GuideStar’s highest level, Platinum.

To achieve platinum level, non-profits must deliver extensive information to the GuideStar Nonprofit Profile including in-depth financial information; quantitative evidence about goals, strategies, and progress toward our mission. By taking the time to provide this information, CCA has demonstrated its commitment to transparency and to giving donors and funders meaningful data to evaluate success.

“For CCA, transparency is key,” said Michael Sapienza, CEO of CCA.  “Our commitment to cancer prevention, cutting-edge research, and providing quality patient support services drives everything we do. We want to share our successes and the impact we’re making. We’re doing meaningful work and our reputation precedes us.”

###

About the Colon Cancer Alliance

The Colon Cancer Alliance is a national nonprofit committed to ending colon cancer within our lifetime. Working with our nation of passionate advocates, we are empowered to support the needs of patients and survivors, eager to raise awareness of preventative screening, and poised to help fund critical research. We are fiercely determined to end colon cancer once and for all. www.ccalliance.org

About GuideStar Nonprofit Profiles

The GuideStar database contains a profile for every tax-exempt nonprofit registered with the IRS. GuideStar encourages every nonprofit to claim and update its profile at no cost to the organization. Updating allows nonprofits to share a wealth of up-to-date information with the more than 7 million people who visit GuideStar to learn more about nonprofit organizations each year.

Colon Cancer Alliance Launches First-Ever Chris4Life Peer-Reviewed Research Program

First Grant to Respond to the Rising Trends in Young-Onset Colorectal Cancer by Awarding Multi-Year Grant to a Qualified Researcher

Washington, DC — The Colon Cancer Alliance is pleased to launch its first-ever Chris4Life Peer-Reviewed research program. The program is titled the Chris4Life Peer Reviewed research program, named in honor of Colon Cancer Alliance’s Founder & CEO’s mother Christine Sapienza who passed away from colon cancer in 2009. Given the rising trends in young-onset colorectal cancer and the recent data released in the Journal of the National Cancer Institute, which indicates that adults born in 1990 have double the risk of colon cancer and quadruple the risk of rectal cancer compared with those born in 1950, this grant cycle will offer opportunities for young-onset colorectal cancer research.

“The Colon Cancer Alliance is dedicated to investing $10 million in life-saving research by 2021,” said CEO Michael Sapienza.  “Through our peer-reviewed research program, our agenda will include understanding why those under 50 are increasingly diagnosed with colorectal cancer and decreasing late-state diagnosis of high-risk populations, advancing precision medicine and immunotherapies and developing better mechanisms for pre-disease and early diagnosis of colorectal cancer. By funding research in these critical areas, we hope to be one step closer to a future free of colon cancer,” Sapienza added.  

The grant selection process will utilize a research proposal review system similar to that of the National Institutes of Health. Research proposals will be reviewed by members of a distinguished Scientific Review Panel. Members of the panel are drawn from outstanding institutions such as:

      • National Cancer Institute
      • M.D. Anderson Cancer Center
      • Fox Chase Cancer Center
      • Georgetown University Lombardi Cancer Center
      • Hofstra-Northwell School of Medicine
      • University of Colorado
      • University of South Carolina

The research proposed for funding may be basic, translational, clinical, or epidemiological in nature and should focus on changes in the microbiome and its impact in the development of young onset colorectal cancer. The underlying goal of the Colon Cancer Alliance’s research program is to provide funding for innovative projects expected to lead to future funding from other peer-reviewed sources.

A multi-year grant in the amount of $125,000 will be awarded at the end of the year, with grant terms to begin January 2, 2018.  Interested investigators can find further details at www.ccalliance.org/get-information/research/apply-research-grant/.   Applications must be submitted no later than 11:59 PM EDT, Thursday, August 31, 2017, using the Colon Cancer Alliance’s on-line application.  Additional inquires may be directed to Stephanie Guiffre at sguiffre@ccalliance.org.

# # #

The Colon Cancer Alliance is a national nonprofit committed to ending colon cancer within our lifetime. Working with our nation of passionate advocates, we are empowered to support the needs of patients and survivors, eager to raise awareness of preventative screening, and poised to help fund critical research. We are fiercely determined to end colon cancer once and for all. www.ccalliance.org

 

Special thanks to Olympus, The Lyons Family and Roanne’s Race for their support of our Research program.